EU-CERT-ICD
Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope
| Coordinatore | UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS
Organization address
address: Robert-Koch-Strasse 40 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.eu-cert-icd.eu/ |
| Totale costo | 7˙681˙938 € |
| EC contributo | 5˙999˙562 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-10-01 - 2017-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS
Organization address
address: Robert-Koch-Strasse 40 contact info |
DE (GOETTINGEN) | coordinator | 1˙695˙023.00 |
| 2 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 465˙120.00 |
| 3 |
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GAB O
Organization address
address: Oskar-von-Miller-Ring 29 contact info |
DE (MUENCHEN) | participant | 395˙232.00 |
| 4 |
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Organization address
address: GESCHWISTER SCHOLL PLATZ 1 contact info |
DE (MUENCHEN) | participant | 377˙765.00 |
| 5 |
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN
Organization address
address: ISMANINGER STRASSE 22 contact info |
DE (MUENCHEN) | participant | 376˙233.00 |
| 6 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 376˙153.00 |
| 7 |
REGION HOVEDSTADEN
Organization address
address: KONGENS VAENGE 2 contact info |
DK (HILLEROD) | participant | 289˙093.00 |
| 8 |
UNIVERSITAETSSPITAL BASEL
Organization address
address: HEBELSTRASSE 32 contact info |
CH (BASEL) | participant | 257˙750.00 |
| 9 |
SEMMELWEIS EGYETEM
Organization address
address: Ulloi ut 26 contact info |
HU (BUDAPEST) | participant | 252˙934.00 |
| 10 |
OULUN YLIOPISTO
Organization address
address: Pentti Kaiteran Katu 1 contact info |
FI (OULU) | participant | 238˙324.00 |
| 11 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | participant | 206˙160.00 |
| 12 |
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Organization address
address: CALLE ROSSELLO 149 PUERTA BJS contact info |
ES (BARCELONA) | participant | 204˙140.00 |
| 13 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 182˙496.00 |
| 14 |
UNIVERSYTET MEDYCZNY W LODZI.
Organization address
address: Al. Kosciuszki, 4 contact info |
PL (LODZ) | participant | 178˙189.00 |
| 15 |
SLOVENSKA ZDRAVOTNICKA UNIVERZITA V BRATISLAVE
Organization address
address: LIMBOVA 12 contact info |
SK (BRATISLAVA) | participant | 142˙416.00 |
| 16 |
ST. PAUL'S CARDIAC ELECTROPHYSIOLOGY LLP
Organization address
address: VERULAM AVENUE 16 contact info |
UK (PURLEY) | participant | 141˙015.00 |
| 17 |
PANEPISTIMIAKO GENIKO NOSOKOMEIO ATTIKON
Organization address
address: ODOS RIMINI 1 contact info |
EL (ATHINA CHAIDARI) | participant | 125˙616.00 |
| 18 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 54˙000.00 |
| 19 |
MAGDALENA - KLINIKA ZA KARDIOVASKULARNE BOLESTI MEDICINSKOG FAKULTETASVEUCILISTA J.J. STROSSMAYERA U OSIJEKU USTANOVA
Organization address
address: LJUDEVITA GAJA 2 contact info |
HR (KRAPINSKE TOPLICE) | participant | 41˙903.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'An estimated 500.000 sudden cardiac deaths (SCD) occur each year in the European Union. Patients at risk for SCD may benefit from prophylactic treatment with an implantable cardioverter-defibrillator (ICD). ICD implantations have dramatically increased in recent years leading to multi-billion Euros of costs with significant regional disparities across Europe. Information on risks, benefits and costs supporting current guideline recommendations may be outdated, and the influence of gender remains unclear. EU-CERT-ICD (Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe) aims to generate contemporary clinical outcome data on ICD effectiveness in Europe. Clinical outcomes including all-cause mortality, appropriate and inappropriate ICD shocks, and quality of life (QoL) are assessed by: - a prospective study of patients undergoing indicated ICD treatment for primary SCD prevention, with a control group of patients not undergoing ICD treatment - a large European registry collecting available data on prophylactic ICD treatment - meta-analyses of available and emerging ICD outcome studies QoL-adjusted cost-effectiveness will be estimated from actual cost comparisons and Markov decision models with attention to sub-groups, regional, and sex comparisons. Outcomes in patients receiving ICDs for primary SCD prevention will be compared in sub-strata, and with patients fulfilling guideline criteria but not undergoing therapy as per prior decision of treating physicians. Sub-groups with particularly large or small benefit from ICD implantation will be identified using risk markers and clinical characteristics with specific emphasis on gender. EU-CERT-ICD is expected to provide important novel information to validate or challenge current guideline indications for primary prophylactic ICD treatment.'
Altri progetti dello stesso programma (FP7-HEALTH)
FRAILOMIC (2013)
"Utility of omic-based biomarkers in characterizing older individuals at risk for frailty, its progression to disability and general consequences to health and well-being - The FRAILOMIC Initiative"
Read MoreEUROHYP-1 (2012)
"European multicentre, randomised, phase III clinical trial of hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke"
Read More